Shanghai Henlius Biotech, Inc. (2696.HK)
HKD 40.35
(3.59%)
HKD 40.35
(3.59%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 3.1 Billion CNY | 3.39% |
| 2022 | 3 Billion CNY | 21.7% |
| 2021 | 2.46 Billion CNY | 243.1% |
| 2020 | 719.3 Million CNY | 142.52% |
| 2019 | -1.69 Billion CNY | -292.53% |
| 2018 | -430.97 Million CNY | -161.57% |
| 2017 | 699.91 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 3.14 Billion CNY | 1.15% |
| 2024 Q2 | 3.14 Billion CNY | 8.39% |
| 2023 Q1 | 3.09 Billion CNY | 3.07% |
| 2023 Q2 | 3.17 Billion CNY | 2.63% |
| 2023 Q4 | 3.1 Billion CNY | -7.38% |
| 2023 FY | 3.1 Billion CNY | 3.39% |
| 2023 Q3 | 3.35 Billion CNY | 5.52% |
| 2022 Q2 | 2.79 Billion CNY | 3.68% |
| 2022 Q4 | 3 Billion CNY | 541.4% |
| 2022 Q3 | -680.47 Million CNY | -124.33% |
| 2022 FY | 3 Billion CNY | 21.7% |
| 2022 Q1 | 2.69 Billion CNY | 9.31% |
| 2021 Q1 | 1.31 Billion CNY | 82.41% |
| 2021 FY | 2.46 Billion CNY | 243.1% |
| 2021 Q4 | 2.46 Billion CNY | 34.02% |
| 2021 Q3 | 1.84 Billion CNY | 34.14% |
| 2021 Q2 | 1.37 Billion CNY | 4.63% |
| 2020 Q2 | -461.11 Million CNY | 9.49% |
| 2020 FY | 719.3 Million CNY | 142.52% |
| 2020 Q4 | 719.3 Million CNY | 11.13% |
| 2020 Q3 | 647.26 Million CNY | 240.37% |
| 2020 Q1 | -509.43 Million CNY | 70.54% |
| 2019 FY | -1.69 Billion CNY | -292.53% |
| 2019 Q1 | -136.95 Million CNY | 70.12% |
| 2019 Q4 | -1.72 Billion CNY | 0.0% |
| 2019 Q3 | -1.72 Billion CNY | -475.76% |
| 2019 Q2 | 460.2 Million CNY | 436.03% |
| 2018 Q3 | -458.28 Million CNY | 0.0% |
| 2018 FY | -430.97 Million CNY | -161.57% |
| 2018 Q4 | -458.28 Million CNY | 0.0% |
| 2018 Q1 | 60.98 Million CNY | 0.0% |
| 2017 FY | 699.91 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | -76.36 Million HKD | 4166.291% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.26 Billion HKD | 41.038% |